We 
Introduction
We are developing an integrated approach that involves novel applications of knowledge representation, ontology development and natural language processing to address major current issues within the pharmaceutical industry. These approaches enable the identification of potential risks that can impact a clinical trial or development of a commercial product that is successful in the marketplace, and additional research is addressing quantitative ways to analyze and prioritize these risks.
The current estimated cost for bringing a new drug to the marketplace is over $1B (US), with the majority of this expense associated with the successful performance of clinical trials to establish both safety and efficacy of the drug. Of particular concern is the observation that only about 9% of all drugs that enter Phase I of clinical studies are successful in receiving approval from regulatory agencies that govern the ability to prescribe and reimburse for their use [1] . And many recent examples exist where drugs have been successful in navigating the clinical trial/regulatory process only to fail in the marketplace because of the occurrence of unanticipated side-effects or efficacy issues, e.g. Vioxx, Avandia. There are significant concerns from both the pharmaceutical sector concerning the impact on financial stability or growth and from the regulators concerning the need to protect the patients from risk and/or inappropriate treatment and cost which need to be addressed. Most pharmaceutical companies are currently developing internal resources to focus on these issues; regulators are looking to technology advances as to their potential for incorporation in the review and approval process. The proof-of-concept developed for this approach is focused on drug repositioning, i.e. taking an existing drug and identifying new clinical applications to take advantage of known safety and efficacy profiles and potentially extend patent lifetime [2] . Additional applications of drug repositioning attempt to take compounds that may have not succeeded in clinical studies for a specific application and try to identify new target opportunities and/or populations. The obvious advantage to this approach is to further leverage the high investment already made into a specific therapeutic, possibly salvage potential failures in clinical trials and reduce full dependency on successful application of the discovery pipeline.
Critical Issues
We would summarize the major issues in clinical trials that we are addressing in our platform as follows:
1. Given both the high cost (>500,000 euros) and high failure rate (>90%) of clinical trials, most pharmaceutical/biotech companies are making significant investments in attempting to improve the rates for clinical trial success and product development [1] 2. Optimal development of exclusion/inclusion criteria can lead to reduced number of patients to be recruited and shorter, more cost-effective clinical trials.
3. The potential user community will be primarily comprised of clinical and molecular scientists and potentially business development and marketing specialists; these individuals do not speak the same "language" 4. Specialists in data aggregation and analysis are becoming more rare in the industry as cost-cutting measures are being implemented across companies 5. Current practice in the commercial environment does not involve the comprehensive analysis of the underlying hypothesis for a clinical trial prior to trial design, i.e. analysis of all related elements in the clinical, molecular and commercial domain 6. Clinical trial failures occur more commonly because of lack of such analysis than because of limitations in actual patient recruitment 7. Enhanced hypothesis development and conversion into trial design and appropriate inclusion/exclusion criteria can reduce the number of patients needed in the trial and shorten the trial length, creating greater value 8. Regulatory agencies are looking to identify standards and methods that can be integrated into their approval process for initial clinical trial review and design approval 9. Critical issues of patient recruitment need to address the gap between clinical trial participation and real world patient populations 10. Incomplete evaluation of critical issues significantly raises the risk for potential trial failure; or, possibly worse, trial success but commercial failure 11. Given the high risk and cost in a clinical trial, commercial companies will only base their trial design and implementation using validated, licensable databases and data repositories rather than public domain data sources.
12. Academic trials, non-industry supported, may utilize public domain data sources but have a higher failure rate and also a more limited conversion into a commercially relevant result than those initiated in the commercial sector.
13. In the effort to reposition a drug for alternative use, the investigator is expected to base the trial on one of three indications: new clinical information concerning the disease; the drug target; or, the effects of the drug, itself.
Approach
SMI has proceeded to develop an ontology-based approach to define the field of drug re-positioning that is both general and extensible to any therapeutic area and integrates the clinical, molecular and commercial domains [3] . This complex ontology is unique and enables linkage and utilization of other conventional ontologies, as may be implemented within a clinical trial design system, but contains concepts and relationships that do not exist in any currently available ontology. This ontology has been used to generate natural language queries, as opposed to pull-down menus, because of user requirements and preferences. These queries can be directly mapped/interpreted using the ontology to identify specific data elements in licensed/validated knowledge/data bases that are used by the client.
This enables relevant data to be "pulled" by the user upon issuing a query rather than have data pushed to the user through the ontology (Picture 1)
Picture 1 Scenario-based Data Pull Model
The proof-of-concept model examines drug repositioning, as noted above and anticipates that the user will enter the problem from one of 3 perspectives: 1) enhanced information about the targeted disease; 2) enhanced information about the drug target; or 3) enhanced information about the drug, itself. The approach, using an ontology that bridges across these primary concepts/perspectives leads from each perspective into a single ontology that represents the state of knowledge about existing clinical, molecular and commercial knowledge, thus expanding the initial perspective into a more global view (Picture 2) which draws data/knowledge from validated data sources, i.e. licensable, commercial data sources rather than public domain data sets [4] .
Picture 2 Ontology Middle Layer
The goal of this platform is to take user-based scenarios, in natural language, and interpret them through the ontology and expand the scope of the queries to reflect the breadth of available and functionally relevant knowledge, and then pull the relevant data from validated data sources to use for establishing more qualified inclusion/exclusion criteria. As evidenced in the top-level diagram of the ontology shown in Picture 3 [5] , the key is to expand the user's initial queries into a more comprehensive interpretation and potential analysis of critical factors that can present risk to trial success, either in the trial itself or in terms of the commercialization efforts that would follow regulatory approval and marketing of the drug.
Picture 3 Ontology Top-Level
It is apparent that while some of the concepts in the ontology, e.g. mutations, SNP's, primary pathways, molecular structure, etc are present in ontologies currently accessible in the public domain, other concepts may be only partially included, e.g. cost, clinical guidelines, conta-indications, and some concepts may not be readily available within accessible ontologies, e.g. intellectual property, commercial development partners, co-morbidities, etc. Of particular interest to the user of the platform is the ability to query the relationships between these concepts, e.g. for Drug-Disease relationships include: current practice guidelines, off-label use, animal models used in testing, etc.
The complexity of the ontology can be seen both in the concepts (using disease examples), e.g.
• Cost includes: cost of manufacturing, cost of drug (retail), reimbursable cost, cost of lost productivity to patient, cost of quality of life, potential costs with no treatment;
• Co-morbidities includes: existing comorbidities, history of co-morbid conditions unique to the patient and also in the general population exhibiting this condition and/or based on age/gender/race/socio-economic status/etc considerations, potential treatments for these conditions, and also in the relationships (using drugdisease examples), e.g.
• clinical practice guidelines: guideline conflicts (multiple governing bodies), physician compliance, patient compliance, quality of decision points, reliability of decision-supporting technologies, e.g. choice of diagnostic test (her2/neu by FISH or IHC);
• animal models: animal model used in safety and efficacy testing, use of this model in similar drug families, effectiveness in moving from animal to man in this disease with this model, presence of SNP's/mutations/strain effects.
Validation of the approach
To evaluate this approach and validate its significance with clinicians, the ontology was applied to "reverse engineer" an existing clinical protocol, THIRST, currently in use in a multi-center cardiac trial for drug repositioning of T3. This study was established to explore the potential treatment of patients with myocardial infarction (MI) so as to prevent progression to dilated heart failure (DHF) through PONTE (an EU FP 7 program) [6] link to specific validated data sets to enable the researcher to comprehensively identify issues at the clinical, molecular and commercial levels. The goal of the validation study was to utilize the ontology (Picture 3) to parse the protocol description and establish two points: 1) that every concept in the trial was already incorporated within the concepts and relationships of the ontology; and 2) that there were a number of concepts and relationships in the ontology that were not contained within the protocol. This latter point leads to the observation of potential risk factors that could arise during the trial and which could have been potentially anticipated by initial analysis of the protocol with CTOP.
The protocol is described below and parsed, as noted, with the appropriate concept and/or relationship from ontology being shown in bold after the protocol segment. It is readily apparent that the protocol is contained within the concepts and relationships of CTOP, but it is also apparent that many such concepts and relationships from the ontology are not represented in the protocol PONTE Protocol [6] "While more patients are surviving an acute myocardial infarction (MI), the incidence of progression to dilated heart failure (HF) has increased (disease concept). Angiotensin Converting Enzyme inhibitors (ACE) and ȕ-blockers (BB), which comprise the state-of-the-art treatments in patients with MI (clinical practice guidelines), have attenuated the process but mortality remains unacceptably high (prognosis). Hence, new treatments that target the fundamental cause of progressive chamber dilatation and HF after MI are needed. The main idea behind this proposal is that Thyroid hormone (TH) system strongly contributes to cardiovascular homeostasis. Transient down-regulation of thyroid function mostly derived from a reduction in biologically active form triiodothyronine (T3), so called low T3 syndrome, is observed during the acute phase of MI that independently from traditional risk factors affects cardiac function and survival (pathophysiology). Compensation of low T3 syndrome may improve cardiac function, quality of life and survival in patients after acute MI (HYPOTHESIS). Replacement therapy with an inexpensive synthetic T3 (Drug Factors) may also reduce health care costs.
TH replacement therapy after acute MI is a potential but insufficiently explored aspect of the management of cardiovascular disease. Several animal studies suggest that low thyroid function contributes to worsening outcome after MI. Ojamaa et al 26 demonstrated the presence of low T3 syndrome in rats after MI. T3 treatment improved ejection fraction and normalized some of the changes in gene expression. In another study, T4 treatment of rats with MI led to a modest improvement in heart function. A study by Olivares et al provides more insight into thyroid hormone impairment in MI. After producing MI in rats, there was a pronounced upregulation of the DIO3 which converts T4 to inactive reverse T3. Serum T3 levels did not normalize for two months (animal studies). DIO3 activity was also found to be increased in skeletal muscle and liver of patients with nonthyroidal illness analyzed shortly after death (comorbidities, secondary pathways). Furthermore, distinct changes in TR receptor expression have been identified during post MI remodeling (target expression levels)".
This initial validation used manual curation and the ontology is currently being implemented into a semantic platform to support automated text mining and protocol analysis. A key aspect of this approach is the extensibility of the ontology to accommodate new concepts and relationships that may be identified by the users, and provide for rapid implementation and dissemination. The interface for the platform encompasses an approach that both supports the comprehensive analysis of the hypothesis and protocol as outlined briefly above, and also enables the user to identify concepts and relationships that may be critical to address their needs in a natural language manner.
User Interface/Natural Language Queries
As stated above, the user interface anticipates users from the clinical, molecular and commercial sectors by presenting questions in a natural language manner. The initial queries are derived from the ontology, linking the concepts through the relationships as shown in Picture 3, and translating these into English language queries. In this manner, these queries become a pseudo-checklist of potential factors to consider for evaluating the hypothesis of the clinical trial and support extension from the initial user perspective to one that integrates across disease/target/drug knowledge using the ontology, and then linking clinical, molecular and commercial knowledge through the mapping from the ontology to the underlying indices of the databases. Examples of such queries, from each of the 3 perspectives of the ontology, are presented below, using the THIRST protocol and clinical condition to establish the context. The actual implementation is disease-agnostic and can be adapted readily to any condition, including behavioral conditions such as alcohol and substance abuse, etc.
Scenario Development 1: Disease Focus
The researcher is interested in exploring the potential treatment of patients with myocardial infarction (MI) so as to prevent progression to dilated heart failure (DHF). The questions should be explored through PONTE and its ontology and thus link to specific validated data sets to enable the researcher to comprehensively identify issues at the clinical, molecular and commercial levels so the he/she can generate a testable hypothesis that will form the basis of the clinical trial to be designed. 
Scenario Development 2: Target(Drugs) Focus
The researcher is interested in exploring the use of the Thyroid Hormone Receptor (THR) as the basis for treatment of patients with myocardial infarction so as to prevent progression to dilated heart failure. The questions should be explored through PONTE and its ontology and thus link to specific validated data sets to It is the goal of this platform to provide not only a more comprehensive approach to hypothesis evaluation and refinement but to enable the user to generate their own queries. These queries would initially be evaluated against the existing ontology to determine the ability to parse them into the current concepts and relationships, and if this is not possible, then extensions to the existing ontology will be added. In this manner, the ontology continues to evolve to capture the existing knowledge in terms of concepts and relationships that are driven by the user's needs and not solely based on database content.
Next steps in development
The platform is currently being used in several pilot studies with pharmaceutical companies to evaluate both clinical trials that have failed as well as trials about to be initiated. The obvious goal of the former is to identify if the platform could have presented the actual risks prior to trial design and implementation; the latter is to predict such risks for new trials.
It should be noted that the current implementation presents the risk factors without a prioritization or quantification of the risk. The collaboration with CNR [7] has been formed to enable such information to be converted into high value risk assessment criteria. Thus the identification of a risk factor will be evaluated as possible to assess its priority or relative risk contribution for evaluation by the trial design team. This is an obvious extension of the initial work that is intended to support the optimal development of adaptive clinical trials as parameters about the trial design can be pre-evaluated with appropriate quantitative methods and incorporated into the protocol, to further optimize the potential trial success.
